PHI with Urinary tract infection
How does this condition affect your private health insurance?
Harnwegsentzündung, commonly known as a Urinary Tract Infection (UTI), is an infection of the urinary system, most often the bladder and urethra. It is primarily caused by bacteria, typically E. coli, entering the urethra. Symptoms include painful and frequent urination, a strong urge to urinate, cloudy urine, and lower abdominal discomfort. While prevalent in women due to anatomy, men can also be affected. If left untreated, the infection can ascend to the kidneys, potentially leading to pyelonephritis, a more serious condition requiring prompt medical intervention to prevent further complications like permanent kidney damage or sepsis.
PKV Risk Assessment
Impact on Your Insurance Policy
Duration of Illness (Initial)
2-7 days with antibiotic treatment; potentially several weeks if untreated.
Duration of Illness (Lifetime)
Often a one-time or infrequent event, but can be a recurring (chronic) condition for some individuals.
Cost of Treatment (Initial)
Approximately 50-200 EUR, including doctor's consultation, urine analysis, and a course of antibiotics.
Cost of Treatment (Lifetime)
Highly variable, ranging from 50 EUR for a single, uncomplicated episode to several thousand EUR for individuals with recurrent infections requiring multiple treatments and diagnostic workups.
Mortality Rate
Extremely low (<0.1%) for uncomplicated cases; increases significantly (up to 20%) in severe, untreated pyelonephritis leading to sepsis, especially in vulnerable populations.
Risk of Secondary Damages
Approximately 5-10% risk of progression to kidney infection (pyelonephritis) if untreated or inadequately treated; rare risk of life-threatening sepsis (<1%).
Probability of Full Recovery
Greater than 95% for uncomplicated cases with appropriate and timely antibiotic treatment, without long-term consequences.
Underlying Disease Risk
Variable. Underlying conditions such as diabetes, urinary tract abnormalities, kidney stones, or a weakened immune system are present in approximately 10-20% of patients, particularly those with recurrent infections.